WEP Clinical (WEP) and Nabriva Therapeutics (Nabriva) are pleased to announce the expansion of the XENLETA (lefamulin) Named Patient Program (NPP) into Australia, New Zealand, Singapore and South Africa.

NPP is designed to ensure that physicians can request IV or oral XENLETA on behalf of individual patients who have an unmet medical need that XENLETA might meet, but who live in countries where XENLETA is not yet commercially available. The XENLETA NPP is also available in the European Union, along with United Kingdom, Iceland, Norway, Switzerland and Liechtenstein. WEP has an exclusive agreement with Nabriva Therapeutics plc (Nabriva) to supply XENLETA on a named patient basis.

XENLETA is approved by the U.S. Food and Drug Administration for the treatment of adults with community-acquired bacterial pneumonia caused by susceptible microorganisms including: Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae. Marketing authorization approval for XENLETA has not yet been granted in Australia, New Zealand, Singapore or South Africa.

Under the terms of the NPP, XENLETA will be made available in two formulations - 150mg injection for intravenous administration and 600mg oral tablets - using the named patient program managed by WEP to enable healthcare professionals to access XENLETA for patients that have an unmet clinical need. Once a request is approved, WEP will manage the distribution of XENLETA to the treating physician and will provide any necessary follow-up support and services.

About WEP Clinical

Established in 2008, WEP Clinical is a specialist services company that works with drug developers to help patients and physicians gain early access to medicines when no other treatment options are available. We have offices located in London, United Kingdom; RTP North Carolina, United States; Lisbon, Portugal and Dublin, Ireland and possess all the necessary licenses allowing us to meet drug access and distribution needs across all regions, worldwide.

About Nabriva Therapeutics

Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA (lefamulin) injections and tablets, the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia. XENLETA was discovered in Nabriva Therapeutics laboratories in Vienna, Austria.

Contact:

Tel: +353 1 649 2000

Email: officeIE@nabriva.com

(C) 2021 Electronic News Publishing, source ENP Newswire